Evidence map›Paper›PMID 32049062›Full record

ArticleJournal of medical Internet research2020

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.

Tjalf Ziemssen, Daniela Piani-Meier, Bryan Bennett, Chloe Johnson, Katie Tinsley, Andrew Trigg, Thomas Hach, Frank Dahlke, Davorka Tomic, Chloe Tolley and 1 more

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Digital Twins for Multiple Sclerosis.Frontiers in immunology · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tjalf ZiemssenCenter of Clinical Neuroscience, Neurological University Clinic Carl Gustav Carus, TU Dresden, Dresden, Germany.ORCID 0000-0001-8799-8202
Daniela Piani-MeierNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0003-0890-9422
Bryan BennettAdelphi Values, Macclesfield, United Kingdom.ORCID 0000-0002-5295-5576
Chloe JohnsonAdelphi Values, Macclesfield, United Kingdom.ORCID 0000-0002-2278-2176
Katie TinsleyAdelphi Values, Macclesfield, United Kingdom.ORCID 0000-0001-9446-9886
Andrew TriggAdelphi Values, Macclesfield, United Kingdom.ORCID 0000-0002-1613-8042
Thomas HachNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0002-2229-1545
Frank DahlkeNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0003-3333-6291
Davorka TomicNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0002-1484-1850
Chloe TolleyAdelphi Values, Macclesfield, United Kingdom.ORCID 0000-0003-3846-9018
Mark S FreedmanOttawa Health Research Institute, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0003-1255-9701

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDefining the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) can be challenging and delayed. A digital tool (MSProDiscuss) was developed to facilitate physician-patient discussion in evaluating early, subtle signs of multiple sclerosis (MS) disease progression representing this transition.

objectiveThis study aimed to determine cut-off values and corresponding sensitivity and specificity for predefined scoring algorithms, with or without including Expanded Disability Status Scale (EDSS) scores, to differentiate between RRMS and SPMS patients and to evaluate psychometric properties.

methodsExperienced neurologists completed the tool for patients with confirmed RRMS or SPMS and those suspected to be transitioning to SPMS. In addition to age and EDSS score, each patient's current disease status (disease activity, symptoms, and its impacts on daily life) was collected while completing the draft tool. Receiver operating characteristic (ROC) curves determined optimal cut-off values (sensitivity and specificity) for the classification of RRMS and SPMS.

resultsTwenty neurologists completed the draft tool for 198 patients. Mean scores for patients with RRMS (n=89), transitioning to SPMS (n=47), and SPMS (n=62) were 38.1 (SD 12.5), 55.2 (SD 11.1), and 69.6 (SD 12.0), respectively (P<.001, each between-groups comparison). Area under the ROC curve (AUC) including and excluding EDSS were for RRMS (including) AUC 0.91, 95% CI 0.87-0.95, RRMS (excluding) AUC 0.88, 95% CI 0.84-0.93, SPMS (including) AUC 0.91, 95% CI 0.86-0.95, and SPMS (excluding) AUC 0.86, 95% CI 0.81-0.91. In the algorithm with EDSS, the optimal cut-off values were ≤51.6 for RRMS patients (sensitivity=0.83; specificity=0.82) and ≥58.9 for SPMS patients (sensitivity=0.82; specificity=0.84). The optimal cut-offs without EDSS were ≤46.3 and ≥57.8 and resulted in similar high sensitivity and specificity (0.76-0.86). The draft tool showed excellent interrater reliability (intraclass correlation coefficient=.95).

conclusionsThe MSProDiscuss tool differentiated RRMS patients from SPMS patients with high sensitivity and specificity. In clinical practice, it may be a useful tool to evaluate early, subtle signs of MS disease progression indicating the evolution of RRMS to SPMS. MSProDiscuss will help assess the current level of progression in an individual patient and facilitate a more informed physician-patient discussion.

Indexed as

AdultDisease ProgressionFemaleHumansMaleMultiple SclerosisPhysiciansReproducibility of ResultsTelemedicinedigitalmultiple sclerosisprogressionrelapsing-remitting multiple sclerosissecondary progressive multiple sclerosistransitionvalidation

Identifiers

PMID32049062
PMCPMC7055760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.